Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nasi, M. L.
Right arrow Articles by Castiglione, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nasi, M. L.
Right arrow Articles by Castiglione, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1169-1171, 2002
© 2002 European Society for Medical Oncology

Editorial

Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled?

M. L. Nasi and M. Castiglione

International Breast Cancer Study Group, Bern, Switzerland (E-mail: mcastiglione@sakk.ch)

The first 150 words of the full text of this article appear below.

Ovarian cancer is the most common gynecological malignancy, as well as the leading cause of death from gynecological cancers in the western world. The survival of patients with advanced epithelial ovarian cancer has clearly improved with the advances in surgery and more effective chemotherapy. Because long-term survival and cure are possible in patients who present with advanced ovarian cancer, the therapeutic strategy generally consists of aggressive surgery combined with chemotherapy. The combination of carboplatin and paclitaxel has been accepted as the treatment of choice, based on the results of large prospective randomized trials. Most patients who present with advanced disease will achieve a clinical complete remission after initial therapy. Unfortunately, the majority of these patients will relapse, and most of the relapsed patients are incurable. Median time to progression (TTP) will vary between 18 and 24 months. Although not curative, treatment of patients with recurrent ovarian cancer can result in . . . [Full Text of this Article]

Based on these findings, should we consider COX-2 expression as a new predictive factor, and possibly also prognostic factor, for patients with ovarian cancer?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Daikoku, D. Wang, S. Tranguch, J. D. Morrow, S. Orsulic, R. N. DuBois, and S. K. Dey
Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer
Cancer Res., May 1, 2005; 65(9): 3735 - 3744.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Agarwal, C. Denkert, and S. Hauptmann
The Function of COX-2 in Human Ovarian Carcinoma
Am. J. Pathol., July 1, 2003; 163(1): 368 - 369.
[Full Text] [PDF]